AU Patent

AU2021241471B2 — Method for treating IDH1 inhibitor-resistant subjects

Assigned to Eli Lilly and Co · Expires 2023-12-14 · 2y expired

What this patent protects

The present invention relates to the treatment of human cancer subjects with a mutant isocitrate dehydrogenase 1 inhibitor of formula I.

USPTO Abstract

The present invention relates to the treatment of human cancer subjects with a mutant isocitrate dehydrogenase 1 inhibitor of formula I.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021241471B2
Jurisdiction
AU
Classification
—
Expires
2023-12-14
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.